Shenzhen Chipscreen Biosciences (688321) Stock Overview
Shenzhen Chipscreen Biosciences Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
688321 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Shenzhen Chipscreen Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.74 |
| 52 Week High | CN¥44.99 |
| 52 Week Low | CN¥23.41 |
| Beta | 0.69 |
| 1 Month Change | 8.09% |
| 3 Month Change | -4.26% |
| 1 Year Change | -7.29% |
| 3 Year Change | 32.93% |
| 5 Year Change | -30.34% |
| Change since IPO | -69.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688321 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 20.0% | 7.4% | -3.0% |
| 1Y | -7.3% | -7.6% | 26.8% |
Return vs Industry: 688321 matched the CN Pharmaceuticals industry which returned -7.6% over the past year.
Return vs Market: 688321 underperformed the CN Market which returned 26.8% over the past year.
Price Volatility
| 688321 volatility | |
|---|---|
| 688321 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688321 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688321's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,002 | Jian-Xun Li | www.chipscreen.com |
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the pharmaceutical industry in China. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma indications; Chiglitazar, a PPAR full agonist for diabetes treatment; Siglitazone for metabolism treatment area; and Cioronib, a novel molecular, which selectively inhibits tumor-related protein kinase targets. It is also involved in the development of CS23546, a small molecule PD-L1 inhibitor, which relieves the immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway; CS231295, a brain-penetrating selective Aurora B inhibitor; and CS32582, a small-molecule allosteric inhibitor of tyrosine kinase 2.
Shenzhen Chipscreen Biosciences Co., Ltd. Fundamentals Summary
| 688321 fundamental statistics | |
|---|---|
| Market cap | CN¥12.73b |
| Earnings (TTM) | CN¥98.39m |
| Revenue (TTM) | CN¥1.00b |
Is 688321 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688321 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.00b |
| Cost of Revenue | CN¥130.44m |
| Gross Profit | CN¥874.39m |
| Other Expenses | CN¥776.01m |
| Earnings | CN¥98.39m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 87.02% |
| Net Profit Margin | 9.79% |
| Debt/Equity Ratio | 59.6% |
How did 688321 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/03 17:22 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shenzhen Chipscreen Biosciences Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yinglan Shu | Haitong International Research Limited |
| Wenxin Yu | Haitong International Research Limited |
| Yuan Yuan Sun | Industrial Securities Co. Ltd. |